Archives of Microbiology Микробиология

Microbial serotonin signalling axes in irritable bowel syndrome: integrative molecular crosstalk among enterochromaffin cells, gut microbiota, neuroimmune circuits, and precision therapeutic engineering

Mehra, Ravinder Kumar, Singh, Bhanu Pratap, Siddiqui, Shakir, Aldawsari, Mohammed F., Kamal, Mohammad Azhar, Anwer, Md. Khalid
Springer Nature · 2026-10-25 · DOI 10.1007/s00203-026-05250-5

Аннотация

Irritable bowel syndrome (IBS) is a common, often disabling disorder of gut–brain interaction whose molecular basis remains incompletely defined, leaving diagnosis largely symptom-based and treatment largely non-mechanistic. We argue that the serotonin (5-hydroxytryptamine; hereafter 5-HT, the primary term used throughout, with “serotonin” retained in less technical contexts) signalling axis-positioned at the interface of the gut microbiota, enterochromaffin (EC) cells, enteric neurons, and the mucosal immune system-is a central, unifying integrator of IBS pathophysiology, and that reframing IBS around this axis offers a route toward mechanism-based subtyping and therapy. We first synthesise how microbiota-driven tryptophan metabolism, short-chain fatty acid and secondary bile acid signalling, and epigenetic regulation of tryptophan hydroxylase 1 (TPH1) shape EC-cell serotonin output, before examining the neuroimmune consequences of dysregulated serotonin secretion-mast cell activation, macrophage polarisation, neurogenic inflammation-and the microbiota–serotonin–gut–brain connectome linking vagal afferent signalling, blood–brain barrier permeability, and central neurotransmitter networks. We then discuss molecular stratification of IBS subtypes through serotonergic endotyping-incorporating SLC6A4 and TPH1 polymorphisms, single-cell transcriptomics, and spatial metabolomics-and critically evaluate next-generation therapeutic strategies, including engineered probiotic chassis, CRISPR-mediated microbial editing, and AI-guided nanomedicine, distinguishing proof-of-concept findings from clinically validated approaches. We conclude that reconceptualising IBS as a disorder of disrupted microbial serotonergic ecosystems, rather than a purely symptom-defined syndrome, offers a coherent and testable framework for biomarker discovery and precision, mechanism-directed therapy, while highlighting the causal-directionality and clinical-translation gaps that must be closed before this framework can be applied at the bedside.

Читать у издателя →